Inland Peptides
Inland Peptides

Sermorelin

Research Snapshot Last reviewed October 2026
Limited

Approved by the FDA for human use

Yes

Studied in human clinical trials

Yes

Published human research

Yes

Published animal research

Primary research areas
  • Growth hormone deficiency

View in catalog →

Overview

Sermorelin is a peptide that matches the first 29 amino acids of growth hormone-releasing hormone. It stimulates the pituitary gland to release the body’s own growth hormone.

Sermorelin was sold in the United States as the FDA-approved medicine Geref. Those products have been discontinued.

What is it being studied for?

Sermorelin was approved for diagnosing and treating growth hormone deficiency in children. Later research looked at age-related decline in growth hormone and at memory in older adults.

Sermorelin acts on the growth hormone-releasing hormone receptor in the pituitary gland.

What has research found?

Human studies supported its use in diagnosing and treating growth hormone deficiency in children. Later small studies examined growth hormone changes in older adults.

Animal studies of this hormone fragment have examined growth hormone release in rats, pigs, and cattle.

Injection site reactions were the most commonly reported side effect during its approved use.

FDA status and development history

Geref was approved for human use and is now discontinued. In 2013, the FDA determined that it had not been withdrawn from sale for reasons of safety or effectiveness. Compounded sermorelin products are not FDA-approved versions of Geref.